Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NSRXBullishCorporate Developmentsnews

High materiality7/10

Nasus Pharma kicks off Phase 1 PK for NS003; topline data by year-end

Sep 29, 2026, 8:13 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestones in Phase 1 PK with topline data by year-end often trigger mood/price moves in small-cap biotech; if PK parity with IV is confirmed and safety is favorable, NSRX could re-rate on development progress and potential TAM expansion.

AI summary

What happened, with direct paths to the underlying reporting

Nasus Pharma announced the first patient dosing in the Phase 1 PK trial of NS003, its intranasal ondansetron powder. Preclinical data showed NS003 achieved a PK profile comparable to IV ondansetron and a favorable safety margin at four times the test dose. Topline PK data are anticipated by year-end, with NS002 pivotal study for anaphylaxis targeted for Q4 2026.

NSRX begins Phase 1 PK for NS003; first patient dosed.
NS003 shows PK parity with IV and strong safety at 4x dose.
Topline PK data expected before year-end 2026; NS002 pivotal for anaphylaxis targeted Q4 2026.
Ondansetron IV widespread; NS003 could offer faster, needle-free option.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Nasus Pharma kicks off Phase 1 PK for NS003; topline data by year-end

Nasus Pharma's NS002 Shows Promise Despite Recent Stock Decline